The Institut Bordet Medical Oncology Clinic has a number of roles:
- diagnosis and therapeutic care of patients with solid tumours
- overseeing administration of cancer medication for in-patients and out-patients
- monitoring patients during and after their treatment.
The Clinic takes a multidisciplinary approach. Therapeutic decisions are made in consultation with other specialist doctors and healthcare professionals involved in the patient’s care.
The aim is that patients should be monitored in all respects, including psychologically.
The Medical Oncology Clinic forms an integral part of the Department of Oncological Medicine. It is also very active in clinical research (particularly in the development of new medication) and translational research. At the Clinic, research is integrated into the care provided, enabling patients to benefit from the latest diagnostic and therapeutic advances, well before these become part of clinical routine.
The Medical Oncology Clinic is divided into 12 sectors:
- thoracic oncology
- urogenital oncology
- breast oncology
- innovative treatments
- endocrine tumour oncology
- bone and soft tissue tumour oncology
- gynaecological oncology
- digestive oncology
- cervico-facial oncology
- skin tumour oncology
- central nervous system oncology.
The Medical Oncology Clinic works in close collaboration with the Institut Bordet Clinical Trials Conduct Unit (CTCU). This unit, which is responsible for the development of new drugs and innovative approaches to care, handles phase I, II and III clinical studies in tumours. The CTCU is made up of research nurses, clinical research associates and data managers who, with research doctors, closely monitor patients taking part in clinical trials.
The Institut’s different research laboratories are also closely linked to the Medical Oncology Clinic. Their principal aim is to identify predictive marker molecules (indicating probability of response to a given treatment) and/or prognosis (chances of a cure) as part of the development of breast cancer treatments.
Recently, the Oncodistinct research network was created. This network brings together numerous researchers who share a common vision of innovative clinical research. The aim of the network is to accelerate the personalisation of treatment and the development of innovative treatments while also promoting a multidisciplinary approach to research and care.
The Institut Bordet Medical Oncology Clinic plays an important role in education, both in Belgium and abroad. Within the hospital, the Clinic’s medical team supervises the training of young doctors and medical students specialising in oncology. Always keen to promote quality training, the Clinic also welcomes many doctors from abroad as part of its Fellowship Programme.
AURORA Programme aimed at understanding the molecular characteristics of recurrent and metastatic breast cancer early in the evolution of metastatic disease.
CHARACTERIZATION OF ENDOCRINE RESISTANT Luminal Breast Cancer using spatial transcriptomics AND epigenetic ANALYSIS.
- Project leaders : Christos Sotiriou, Françoise Rothé and Mattia Rediti
- Collaborations :
- Dr François Fuks, Laboratory of Cancer Epigenetics, ULB-Cancer Research Center (U-CRC), Université libre de Bruxelles
- Prof Lundeberg at the SciLife laboratory, Stockholm, Sweden
- Dr Frédérick Libert, ULB/VUB Brightcore sequencing facility
ZENITH: A PHASE 2 STUDY OF ZEN003694 IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH TRIPLE-NEGATIVE BREAST CANCER (BRCA1 OR BRCA2 NON MUTATED)
- Project leader : Philippe Aftimos
- Collaborations : International clinical study
- Funding (or) Support : Zenith Epigenetics Ltd.
Head of the Medical Oncology Clinic
Pr A. Awada
Pr M. Piccart, Dr D. de Valeriola
Dr Ph. Aftimos, Dr A. Gombos
Pr Ch. Sotiriou, Dr E. de Azambuja
Dr M. Ignatiadis, Dr F. Lebrun
Dr L. Buisseret, Dr L. Polastro
Pr A. Drowart, Dr D. t’Kint de Roodenbeke
Dr Y. Lalami
Pr Th. Berghmans
Dr D. t’Kint de Roodenbeke
Pr J. Klastersky (internal medicine/oncology)
Pr B. Desmarez (gastroenterology/endoscopy)
Dr Z. El Ali (medical oncology)
Dr E. Girard (oncologie médicale/digestive)
Dr P. Gkolfakis (gastroentérologie/endoscopie)
Dr Y. Gökburun (gastroenterology/medical oncology)
Dr D. Levacq (medical oncology/oncogenetics)
Dr A. Lepida (gastroenterology/hepatology)
Dr H. Louis (gastroenterology/digestive functional disorders)
Dr F. Mana (gastroenterology/endoscopy)
Pr A. Van Gossum (endoscopy/gastroenterology/nutrition)
Prognostic value of a three-scale grading system based on combining molecular imaging with <sup>68</sup>Ga-DOTATATE and <sup>18</sup>F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias.
Authors : Karfis I, Marin G, Levillain H, Drisis S, Muteganya R, Critchi G, Taraji-Schiltz L, Guix CA, Shaza L, Elbachiri M, Mans L, Machiels G, Hendlisz A, Flamen P
Year : 2020
Journal : Oncotarget
Volume : 11
Pages : 589-599
The Impact of Thyroid Disorders on Clinical Pregnancy Outcomes in a Real-World Study Setting.
Authors : Sitoris G, Veltri F, Kleynen P, Cogan A, Belhomme J, Rozenberg S, Pepersack T, Poppe K
Year : 2020
Journal : Thyroid
Volume : 30
Pages : 106-115
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers into breast cancer clinical trials and daily practice.
Authors : Gonzalez-Ericsson PI, Stovgaard ES, Sua LF, Reisenbichler E, Kos Z, Carter JM, Michiels S, Le Quesne J, Nielsen TO, Lænkholm AV, Fox SB, Adam J, Bartlett JM, Rimm DL, Quinn C, Peeters D, Dieci MV, Vincent-Salomon A, Cree I, Hida AI, Balko JM, Haynes HR, Frahm I, Acosta-Haab G, Balancin M, Bellolio E, Yang W, Kirtani P, Sugie T, Ehinger A, Castaneda CA, Kok M, McArthur H, Siziopikou K, Badve S, Fineberg S, Gown A, Viale G, Schnitt SJ, Pruneri G, Penault-Llorca F, Hewitt S, Thompson EA, Allison KH, Symmans WF, Bellizzi AM, Brogi E, Moore DA, Larsimont D, Dillon DA, Lazar A, Lien H, Goetz MP, Broeckx G, El Bairi K, Harbeck N, Cimino-Mathews A, Sotiriou C, Adams S, Liu SW, Loibl S, Chen IC, Lakhani SR, Juco JW, Denkert C, Blackley EF, Demaria S, Leon-Ferre R, Gluz O, Zardavas D, Emancipator K, Ely S, Loi S, Salgado R, Sanders M
Year : 2020
Journal : J Pathol
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
Authors : Delaloge S, Piccart-Gebhart M, Rutgers E, Litière S, van t Veer LJ, van den Berkmortel F, Brain E, Dudek-Peric A, Gil-Gil M, Gomez P, Hilbers FS, Khalil Z, Knox S, Kuemmel S, Kunz G, Lesur A, Pierga JY, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Thompson AM, Viale G, Zoppoli G, Vuylsteke P, Tryfonidis K, Poncet C, Bogaerts J, Cardoso F
Year : 2020
Journal : J Clin Oncol
Pages : JCO1901371
Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance Short Title: Sensitivity Prediction to MAPK Inhibitors in Melanoma.
Authors : Krayem M, Aftimos P, Najem A, van den Hooven T, van den Berg A, Hovestad-Bijl L, de Wijn R, Hilhorst R, Ruijtenbeek R, Sabbah M, Kerger J, Awada A, Journe F, Ghanem GE
Year : 2020
Journal : Cancers (Basel)
Volume : 12